ArticleClinical, cosmetic and investigational dermatology2026
Myxoid Onychomatricoma with Unusual CD99 Expression: A Report of a Rare Case and Literature Review.
Article in Clinical, cosmetic and investigational dermatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Onychomatricoma (OM) is a rare, benign fibroepithelial tumor originating from the nail matrix, with different clinical and histological variants documented in existing studies. Myxoid OM is an even rarer subtype, characterized by a prominent fibromyxoid component in histopathology. We report a case of a 34-year-old male patient presenting with clinical manifestations consistent with typical OM. Histopathological examination revealed a biphasic tumor composed of an epithelial component and a prominent myxoid stroma, suggesting a diagnosis of myxoid OM. Notably, the tumor exhibited diffuse CD99 positivity, an extremely rare finding in OM. Histopathologically, myxoid OM shows considerable morphological overlap with superficial acral fibromyxoma (SAFM). Our case illustrates that CD99 positivity cannot serve as an absolute criterion to exclude OM; cautious interpretation of this marker is required to avoid diagnostic pitfalls in the differential diagnosis of these two entities. This case expands the immunophenotypic spectrum of myxoid OM and offers a valuable reference for its differential diagnosis. Furthermore, we include and provide a descriptive review to summarize the clinicopathological features and key differential diagnostic considerations of OM, with a focus on diagnostic pitfalls arising from rare histological variants and atypical immunophenotypes, to facilitate accurate differential diagnosis of subungual tumors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.